GLP-1 RAs appear to primarily reduce MACE, with an apparent focus on non-fatal MI and stroke [10,11,82,83]
Calculation of sample size The G*Power software (version 3.1.9.7) was used to determine the sample size, predicated upon an expected moderate-effect size ( f = 0.25) for detecting intergroup differences in the primary outcome (DAS28-CRP)
This aspect of personalized geroscience could improve treatment outcomes, tailoring therapeutic approaches to an individuals distinct organ aging characteristics in addition to their chronological age
Optum Rx has introduced a host of tools at the formulary and benefit design levels, to ensure GLP-1 drugs are used responsibly
Pay using FSA or HSA funds
Your essential GLP-1 preparation checklist before first dose appointment should include: Confirming your prescription (Wegovy or Zepbound) is filled